7th ICHNO Abstract book

7th ICHNO 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ page 27

whom had adjuvant glottic RT. 31 patients were primarily treated with RT, with a median dose of 63 Gy in 2.25 Gy/fraction. RT patients were older (median age 72 vs 63 years, p=0.01) and had a higher T stage (39% T1b vs 11%, p=0.0008). 201 patients were eligible for analysis (172 S group, 29 RT group), with a median follow-up of 3.2 years (0.3-10.1). There was no difference in 2y-LC (91% S, 97% RT) and 5y- LC (78% S, 92% RT, p=0.16), 5y-DFS (68% S, 78% RT, p=0.49), 5y-UDFS (83% S, 86% RT, p=0.91), 5y-LFS (87% S, 92% RT, p=0.58) and 5y-OS (85% S, 86% RT, p=82). Neither RT fractionation (2.25 vs 2Gy) nor overall treatment time had an impact on locoregional control. Overall, 33 (16%) patients had a recurrence, 30 (17%) in the S group and 3 (10%) in the RT group. Most were local relapses (28 S, 2 RT). Eight (4%) patients had regional failure (7 S, 1 RT), of whom 3 (1%) had local control (2 S, 1 RT). Only 4 (2%) patients eventually developed distant metastasis (3 S group, 1 RT group), all with local and/or regional failure. The most common form of salvage therapy after the first recurrence was larynx-sparing surgery alone (11 S) or with adjuvant treatment (3 S), total laryngectomy (10 S, 2 RT) and RT alone (4 S). Eight of the patients that were salvaged underwent repeat salvage with total laryngectomy (4) or larynx-sparing surgery (4), all in the S group. Overall, of all those that were salvaged, 17 (8%) underwent total laryngectomy (15 S, 2 RT).

Conclusion Our outcomes for T1N0 glottic cancer are excellent, despite the differences in groups. Primary surgery or radiotherapy were equivalent first line options, since they do not differ in all outcomes, including laryngeal preservation rates. Patients’ and physician’s preferences must be considered when choosing first treatment PO-052 T3 Laryngeal SCC: a mono- institutional retrospective analysis of different therapeutic approaches A. Bacigalupo 1 , L. Belgioia 2 , E. Tornari 1 , S. Vecchio 3 , M. Filauro 4 , F. Marchi 4 , G. Peretti 4 , R. Corvò 2 1 Policlinico San Martino, Radiation therapy, Genova, Italy; 2 University of Genoa, Health Science Department DISSAL- Radiation Oncology, Genova, Italy; 3 Policlinico San Martino, Medical Oncology, Genova, Italy ; 4 University of Genoa, Department of Otorinolaringology- Head and Neck Surgery, Genova, Italy Purpose or Objective Optimal treatment for T3 laryngeal cancer is still considered a “grey zone”. Different approaches are available: open partial laryngectomies (OPHL), transoral